Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer.
Koutras
Angelos K
AK
Mastronikolis
Nicholas S
NS
Evans
T R Jeffry
TR
Papadeas
Evangelos S
ES
Makatsoris
Thomas
T
Kalofonos
Haralabos P
HP
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004244:Dizziness / Q000139:chemically induced / Q000628:therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D005260:Female; D006309:Hearing / Q000187:drug effects*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011788:Quality of Life; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D014012:Tinnitus / Q000139:chemically induced / Q000628:therapy; D017211:Treatment Failure
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors